Dilon Technologies Announces a Transportable Version of the Dilon 6800 Gamma Camera

Tuesday, August 12, 2008 General News J E 4
NEWPORT NEWS, Va., Aug. 12 Dilon Technologies, thedesigner and manufacturer of a gamma imaging system optimized for early breastcancer detection, today introduced the Dilon 6800 Access, a transportableversion of the Dilon 6800 Gamma Camera designed to meet the needs of customersthat want to move the camera between medical centers.

The transportable camera will expand the clinical utility of the Dilon6800, by providing the flexibility of transporting the camera to areas of needthat may not have high enough patient volumes to justify a full-timesystem -- such as small community hospitals. The flexibility of the new Dilon6800 Access offers a broad range of added value by enhancing diagnosticcapabilities, increasing revenue and controlling costs.

Shared Medical Technology (SMT) in Rice Lake, Wisconsin is the firstcenter to use the Dilon 6800 Access. SMT has been providing communityhospitals and clinics with top notch diagnostic services for over 30 years.Covering a wide variety of diagnostic tests, SMT provides registered/certifiedtechnologists and quality services, allowing for the local hospitals to offerthe most advanced medical care. For more information on SMT please visit

About Dilon Technologies

Dilon Technologies is bringing innovative new medical imaging products tomarket. Dilon's cornerstone product, the Dilon 6800, is a high-resolution,small field-of-view gamma camera, optimized to perform Breast-Specific GammaImaging (BSGI), a molecular breast imaging procedure which images themetabolic activity of breast lesions through radiotracer uptake. Many leadingmedical centers around the country are now offering BSGI to their patients,including: Cornell University Medical Center, New York; George WashingtonUniversity Medical Center, Washington, D.C; and The Rose, Houston. For moreinformation on Dilon Technologies please visit

SOURCE Dilon Technologies


You May Also Like

View All

Post your Comments

Comments should be on the topic and should not be abusive. The editorial team reserves the right to review and moderate the comments posted on the site.
User Avatar
* Your comment can be maximum of 2500 characters
I agree to the terms and conditions
Nventa Biopharmaceuticals Corporation Announces Se...
Dendreon Reports Second Quarter 2008 Financial Res...